PAVmed Inc.
PAVM Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$2.26
KIRA · Stoqly’s AI analyst, in plain words
- PAVmed Inc. had $0.1M of revenue in fiscal 2025, down 97.6% on the year before.
- Its operating margin was −30,712.7%, down 29,229.8 pts: of every 100 in sales, about −30,713 is left after running the business.
- PAVmed Inc. made $0.4M of net profit in fiscal 2025.
- Free cash flow was −$5.2M in fiscal 2025, −7,376.1% of revenue.
Market cap
$14.2M
P/E
2.1x
Revenue
$0.1M
Net income
$0.4M
Free cash flow
−$5.2M
Operating margin
−30,712.7%
PAVmed Inc. in 30 seconds · fiscal 2025
Are sales growing?
−97.6%
No. Sales fell 97.6% last year.
Does it make a profit?
564.8%
Yes. It keeps 564.8% of every sale as profit.
Does profit turn into cash?
−7,376.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
2.1x
One share costs 2.1 times its yearly profit per share.
What PAVmed Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- PAVmed Inc.
- CIK
- 0001624326
PAVmed Inc. · PAVM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.5M | $0.4M | $2.5M | $3.0M | $0.1M |
| Revenue growth | — | −24.6% | 563.1% | 20.0% | −97.6% |
| Gross margin | −17.0% | −858.6% | −156.8% | −61.3% | −207.0% |
| Operating margin | −10,878.6% | −24,161.0% | −2,751.8% | −1,482.9% | −30,712.7% |
| Net income | −$50.3M | −$89.0M | −$64.2M | $39.8M | $0.4M |
| Net margin | −10,069.4% | −23,602.9% | −2,567.0% | 1,326.4% | 564.8% |
| Diluted EPS | −$0.65 | −$15.03 | −$9.16 | $14.90 | −$5.63 |
| Cash | |||||
| Cash from operations | −$40.6M | −$71.0M | −$52.0M | −$33.6M | −$5.2M |
| Capital expenditure | $1.5M | $1.5M | $0.2M | $0.1M | $0.0M |
| Free cash flow | −$42.1M | −$72.5M | −$52.3M | −$33.6M | −$5.2M |
| FCF margin | −8,412.0% | −19,237.4% | −2,091.1% | −1,120.3% | −7,376.1% |
| Share count change | 63.4% | −92.3% | 21.8% | −69.9% | −69.1% |
| Debt and strength | |||||
| Cash and short-term investments | $77.3M | $39.7M | $19.6M | $1.2M | $1.5M |
| Shareholders' equity | $61.7M | −$9.7M | −$53.8M | −$2.5M | $34.0M |
| Current ratio | 10.9x | 1.1x | 0.5x | 0.1x | 0.2x |
| Interest coverage | — | −71.1x | −116.8x | −988.6x | −1,038.4x |
| Returns and quality | |||||
| Return on equity | −158.4% | −342.3% | — | — | 2.5% |
| Return on tangible equity | −84.9% | — | — | — | −11.1% |
| Piotroski F-score | — | 3 | 3 | 5 | 3 |
| Altman Z'' | 4.8 | −25.0 | −49.8 | −44.1 | −25.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
PAVmed Inc. · PAVM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.26 a share, the company is worth $14.2M: 2.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001624326). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.